This is the authors' abstract. We don't add key points for this paper.
Epstein-Barr virus (EBV) infection and reactivation is an increasing complication in immune deficient patients, particularly after allogeneic hematopoietic stem cell transplantation (HSCT). Therapy with anti-thymocyte globulin (ATG) is associated with higher incidence of EBV-related disease in HSCT patients, but this risk is not documented in patients receiving ATG for severe aplastic anemia (SAA). We describe the case of a patient who developed an EBV infection, with the clinical features of an infectious mononucleosis, after immune suppression with cyclosporine and two courses of ATG for SAA.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Calistri et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: